Edition:
United States

Pain Therapeutics Inc (PTIE.O)

PTIE.O on Nasdaq

2.70USD
25 Jul 2016
Change (% chg)

$0.06 (+2.27%)
Prev Close
$2.64
Open
$2.64
Day's High
$2.77
Day's Low
$2.64
Volume
224,158
Avg. Vol
112,157
52-wk High
$2.77
52-wk Low
$1.53

Latest Key Developments (Source: Significant Developments)

Pain Therapeutics Q2 loss per share $0.07
Tuesday, 19 Jul 2016 04:30pm EDT 

Pain Therapeutics Inc : Pain Therapeutics reports Q2 2016 financial results .Q2 loss per share $0.07.  Full Article

Durect says PDUFA date for remoxy NDA of Sept 25 unchanged
Friday, 1 Jul 2016 09:05am EDT 

Durect Corp : Says prescription drug user fee act (PDUFA) date for remoxy NDA of September 25, 2016 is unchanged . An FDA advisory committee meeting for remoxy is not needed and no change to September 25, 2016 PDUFA date . Pain Therapeutics stated that FDA advised them that regulatory review of remoxy new drug application (NDA) remains active and on-going .Durect provides remoxy update.  Full Article

Pain Therapeutics announces positive top-line results from Human Abuse Potential Study With REMOXY
Tuesday, 12 May 2015 08:01am EDT 

Pain Therapeutics Inc:Announces top-line results of an FDA Category 3 Human Abuse Potential Study with REMOXY Extended-Release Capsules CII, its lead drug candidate that is specifically designed to discourage certain common methods of drug tampering and misuse.This study demonstrated with statistical significance ( p <0.0001) that both intact and chewed REMOXY were less "liked" than immediate-release oxycodone on the two primary endpoints, Drug Liking and Drug High.The Abuse Potential study was conducted in non-dependent, recreational opioid users, as recommended by FDA guidelines.  Full Article

Pain Therapeutics Inc announces material definitive agreement - Form 8-K
Wednesday, 6 May 2015 06:04am EDT 

Pain Therapeutics Inc:Says sent letter to Durect Corp. pursuant to development and license agreement, dated as of Dec. 19, 2002.As amended (DLA), that provided Durect with formal written notice that company is deleting, effective as of Jan. 12, 2015, opioid drug hydrocodone (and only hydrocodone) as a licensed product under the DLA.Letter does not alter terms of DLA regarding remaining three licensed products (REMOXY, hydromorphone or oxymorphone) or otherwise amend the DLA.For avoidance of doubt, all terms and conditions of DLA remain in full force and effect with respect to REMOXY, hydromorphone and oxymorphone.  Full Article

Pfizer to discontinue agreement on REMOXY extended-release capsules CII with Pain Therapeutics, Inc
Monday, 27 Oct 2014 08:00am EDT 

Pfizer Inc:To discontinue its agreement to develop and commercialize REMOXY (oxycodone) Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone.To return all rights, including responsibility for regulatory activities, to Pain Therapeutics, Inc.  Full Article

BRIEF-Pain Therapeutics Q2 loss per share $0.07

* Q2 loss per share $0.07 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)